Phase 2 N=101 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=97 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Childhood Cerebral Anaplastic Astrocytoma · Childhood Oligodendroglioma · Childhood Spinal Cord Neoplasm
Primary: Objective Response Rate Sustained for ≥ 8 Weeks — 0; 0; 0; 0 participants
Phase 2 N=15 Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
HIV Infections
Primary: Anti-Tat Antibody Titer — 401; 887 ng/mL
Phase 2 N=20 Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Major Depressive Disorder
Primary: Feasibility — 33 screens
Phase 2 N=94 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants
Phase 2 N=21 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Glioblastoma · Gliosarcoma
Primary: Progression-free Survival at 6 Months — 61.9 percentage of participants
Phase 2 N=90 Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Major Morbidity Related to the Intact Primary Tumor — 16.3 probability of major morbidity (%)
Phase 2 N=16 AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms
Primary: Percentage of Participants With a Repeat Paracentesis Response (RPR) — 62.5 percentage of participants
Phase 2 N=101 Treatment With Pazopanib for Neoadjuvant Breast Cancer
Neoplasms, Breast
Primary: Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes — 16 Participants
Phase 2 N=135 A Study of Econazole Foam 1% in Athlete's Foot
Tinea Pedis · Athlete's Foot
Primary: Complete Cure Rate: Interdigital Disease — 9; 9; 1 Participants
Phase 2 N=29 A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Synovial Tissue Messenger Ribonucleic Acid (mRNA) Expression at Day 28 — -2.73; -2.83; -3.72; -3.96 relative expression unit (REU)
Phase 2 N=150 iCare Stress Management e-Training for Dementia Family Caregivers
Alzheimer's Disease · Dementia
Primary: Perceived Stress Scale — 15.83; 16.41 units on a scale
Phase 2 N=509 Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 47.14; 55.88; 56.34; 58.11 percentage of participants
Phase 2 N=1 Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Ovarian Cancer
Primary: Progression Free Survival — 54 day
Phase 2 N=24 Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.
Prostate Cancer
Primary: Adverse Event — 22; 2; 4; 0 Adverse Events — p=0.001